PDCD1 and cancer: Our analyses showed that anti-PD-1/PD-L1 responder and non-relapsed tumors had a higher percentage of epithelial Ecad+ cancer cells than non-responder and relapsed tumors (Fig. 7a–c, g, k and  Supplementary Fig. 8a, f, k).